Storia in 2 fonti

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Roughly one in five patients ditched survodutide due to adverse events

Raccontata da

healio.com

medpagetoday.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mese fa

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Roughly one in five patients ditched survodutide due to adverse events

originale

healio.com1 mese fa

Weekly survodutide confers dual benefits for obesity, metabolic liver disease

NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic dysfunction-associated steatotic liver disease.Researchers…

Leggi questa versione → originale

Timeline cronologica

domenica 7 giugno 2026·healio.com
Weekly survodutide confers dual benefits for obesity, metabolic liver disease
NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic…
lunedì 8 giugno 2026·medpagetoday.com
Monthly GLP-1 for Obesity Promising as More Manageable Alternative
Less frequent dosing could support better long-term adherence, says researcher

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Weekly survodutide confers dual benefits for obesity, metabolic liver disease

Timeline cronologica

Weekly survodutide confers dual benefits for obesity, metabolic liver disease

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD